Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Journal of Clinical Oncology.
Times cited: 105
Prolonged early G 1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Times cited: 35